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Abstract
Matrix metalloproteinases (MMPs) have long been linked to cancer progression owing to their
ability to breakdown tissue barriers for metastatic spread. Accordingly, multiple studies have
examined the potential value of these enzymes as targets for cancer therapy. Unfortunately, most
clinical trials with MMP inhibitors have yielded negative results which has made necessary to re-
evaluate the role of these proteases in cancer. Recent works mainly based on the use of mouse
models deficient in specific MMPs have revealed that these enzymes play many roles in cancer
distinct from matrix destruction, influencing early steps of tumor evolution, and expanding their
pro-tumorigenic properties. However, these in vivo studies have also shown that, unexpectedly,
some MMP family members like MMP8 may have paradoxical anti-tumor functions.
Nevertheless, the final validation of these MMPs as bona fide tumor suppressors requested the
identification of the putative genetic or epigenetic changes underlying their inactivation during
cancer development. To this purpose, very recent large-scale genomic studies have explored the
possibility that MMPs could be genetically altered in a panel of human malignant tumors from
different sources. These studies have demonstrated that MMP8 is a frequently mutated gene in
human melanoma. Functional analysis of the identified mutations has confirmed that all of them
lead to the loss-of-function of MMP8 and enhance the progression of melanoma, thus providing
definitive evidence that MMP8 is a tumor-suppressor gene. Parallel studies have extended these
findings to other MMP-related metalloproteinases such as ADAMTS15, which has been found to
be genetically inactivated in human colorectal cancer. This review describes the identification and
validation of some MMPs and related enzymes as anti-tumor proteases and speculates about the
molecular mechanisms underlying their protective roles in tumor development. Finally, the review
explores the clinical applications derived from the identification of MMPs that favour the host
instead of the tumor.
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The Place of MMPs in the Human Degradome
Proteases play essential roles in a wide variety of biological processes and are also
associated with multiple diseases, including cancer.1 This large and growing functional
diversity of proteolytic enzymes derives from the occurrence in all organisms of a high
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number of proteins with different sizes, shapes and catalytic properties but with the common
ability to hydrolyze peptide bonds. Analysis of the human genome sequence has shown that
our degradome—the complete set of proteases produced by human cells and tissues—is
composed of at least 569 proteases or protease-like proteins classified into five catalytic
classes and 68 families. Interestingly, the mouse degradome is even more complex and
consists of at least 644 proteases and homologues.2 Among this variety of proteolytic
enzymes, the matrix metalloproteinases (MMPs)—encoded by 24 distinct genes in human
and 23 genes in mouse—have long been considered as important effectors in cancer
progression due to their ability to degrade the main protein components of the extracellular
matrix and basement membranes, thereby providing an access for tumor cells to the vascular
and lymphatic systems and facilitating the generation of metastasis.
Based on this idea, over the last years there has been a sustained interest in the structural and
functional characterization of all members of this family of metalloproteinases.3 MMPs can
be classified into four groups according to their domain organization. The archetypal MMPs,
including collagenases and stromelysins, contain a signal peptide necessary for secretion, a
propeptide involved in the maintenance of enzyme latency, a catalytic domain that binds
zinc and a hemopexin C-terminal domain important in determining substrate specificity and
interactions with tissue inhibitors of metalloproteases. Matrilysins contain the minimal
domain organization that is necessary for secretion, latency and catalytic activity but lack
the hemopexin C-terminal domain. Gelatinases incorporate three fibronectin II modules
within the catalytic domain which improve collagen and gelatin degradation. Finally,
convertase-activatable MMPs have a basic insert in the prodomain that is cleaved by furin-
like proteases. Among the MMPs that belong to this group there are secreted enzymes or
membrane-bound proteins via GPI (glycosylphosphatidylinositol), type I or type II
transmembrane segments. Consistent with this structural diversity, MMPs play multiple
functions beyond their direct contribution to the degradation of tissue barriers and influence
cell behavior, survival and death in many physiological and pathological processes including
cancer.
Links Between MMPs and Cancer
The association between MMPs and cancer can be traced back to the 1970s when several
studies identified pro-metastatic activities linked to the presence of members of the MMP
family such as gelatinases.4 However, further studies over the next three decades have
shown that the role of MMPs in cancer progression is much more complex than that derived
from their contribution to the late invasive stages of the tumorigenic process. Thus, we now
recognize that MMPs may target growth-factor receptors, cytokines, chemokines, cell
adhesion molecules, apoptotic ligands and angiogenic factors and contribute to all stages of
tumor progression, including proliferation, adhesion, migration, angiogenesis, senescence,
apoptosis and evasion of the immune system.5 This wide functional diversity of MMPs in
cancer biology together with the establishment of causal relationships between MMP
overexpression in tumor or stromal cells and cancer progression prompted the development
of clinical trials with a first generation of inhibitors designed to block the proteolytic activity
of these enzymes. However, most of these clinical trials using broad-spectrum MMP
inhibitors (MMPIs) for the treatment of patients with advanced cancer have yielded
disappointing results.6 There are several putative explanations for the poor outcome of these
MMPIs, mostly derived from the previous ignorance about the wide structural and
functional complexity of this protease family.7 In fact, just three MMPs (MMP1, MMP2 and
MMP3) had been described when the first clinical trials with MMPIs were designed. The
subsequent discovery of more than 20 distinct MMPs and the identification of the two
related families of metalloproteinases called ADAMs (A Disintegrin And Metalloproteinase)
and ADAMTSs (ADAMs with ThromboSpondin domains) which can be also inhibited by
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MMPIs, has made necessary the re-evaluation of the specificity of the inhibitors used in the
clinical trials. Additionally, the finding that MMPs are crucial in the early stages of tumor
progression suggests that their contribution might be less relevant once metastasis have been
generated, thus minimizing the putative beneficial effects of MMPIs administered to cancer
patients with advanced disease. Finally, the lack of positive results with MMPI-based trials
could also have been derived from deficiencies in the selection of the specific MMP family
members which should be targeted in cancer. Thus, the observation that in some patients
treated with broad-spectrum MMPIs there was an apparent exacerbation of tumor growth,
suggested the possibility that some MMPs might have paradoxical anti-tumor roles. Further
studies based on the generation of genetically modified mouse models of loss-of-MMP
function have recently provided definitive evidence on the protective role of some MMPs in
cancer.
MMPs with Anti-Tumor Properties
After years of considering MMPs as pro-tumorigenic enzymes, studies with mutant mice
deficient in MMP8 demonstrated for the first time the in vivo anti-tumor properties of a
member of this protease family.8 MMP8 or collagenase-2 is mainly produced by neutrophils
and has been implicated in a variety of inflammatory conditions. The unexpected finding
that MMP8 has tumor-defying functions derived from the observation that the absence of
this protease in MMP8-null mice strongly increased the incidence of skin tumors in these
animals. Bone-marrow transplantation experiments in MMP8-deficient mice revealed that
neutrophil-derived MMP8 is sufficient to rescue the anti-tumor protection conferred by this
metalloproteinase. Molecular and histopathological studies aimed at evaluating the
mechanisms underlying the protective function of MMP8 have indicated that the loss of this
protease causes important deficiencies in the inflammatory response induced by chemical
carcinogens, finally resulting in a sustained inflammation that creates a favorable
microenvironment for cancer progression. Further studies have shown that this protective
function of MMP8 is likely linked to its ability to participate in the proteolytic processing of
inflammatory mediators rather than to its classical role as an efficient collagenase implicated
in the degradation of fibrillar collagens.8,9 Consistent with these studies in mice,
experimental manipulation of MMP8 expression levels in human breast cancer cells has
demonstrated that downregulation of this protease in non-metastatic cells increases its
metastatic potential, whereas its overexpression in metastatic cells substantially reduces this
potential.10 Recent experiments using MMP8-null mice and syngenic melanoma and lung
carcinoma cells overexpressing MMP8 have extended these findings and demonstrated that
this metalloproteinase functions as a metastasis suppressor through the modulation of tumor
cell adhesion and invasion.11 Finally, analysis of MMP8 expression in human breast
carcinomas has revealed that the presence of this enzyme correlates with a lower incidence
of metastasis and confers a good prognosis to breast cancer patients. It is also remarkable
that similar findings have been reported for patients with oral carcinomas.12 Likewise, and
also consistent with the above observations, a high-expression allele of the MMP8 gene is
associated with lower susceptibility to metastasis and better survival in breast cancer
patients.13
Parallel studies have shown that other MMP family members distinct from MMP8,
including MMP12 (macrophage metalloelastase) and MMP26 (matri-lysin-2) can also
develop anti-tumor functions in different stages of cancer progression.14–16 Furthermore,
other MMPs such as MMP3 (stromelysin-1), MMP9 (gelatinase-B), MMP11 (stromelysin-3)
and MMP19, which were originally described as protumorigenic enzymes, appear to play
dual roles in cancer and exhibit protective roles in some specific circumstances (reviewed in
ref. 17).
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Taken collectively, the above findings have provided strong support to the idea that there are
several MMPs with the ability to negatively control some aspects of cancer progression, thus
favoring the host instead of the tumor. The occurrence of anti-tumor MMPs has also
provided some explanations for the lack of success of clinical trials based on the use of a
first generation of broad-spectrum MMPIs for cancer therapy. Nevertheless, these
observations are still preliminary in many aspects and further studies are necessary to
elucidate the molecular mechanisms underlying the cancer-defying functions of the anti-
tumor MMPs. Likewise, it is essential to clarify the putative genetic or epigenetic alterations
which must undergo these MMPs during tumor progression in order to be validated as bona
fide tumor-suppressor genes. Fortunately, very recent studies derived from the availability of
the results from large-scale analysis of cancer genomes, have shed light on this important
question.
High Throughput Sequencing of Gene Families in Human Cancer
The above discoveries suggested that MMPs might be genetically altered in human cancer.
One way to definitely implicate a gene to human cancer is to discover tumor-specific
mutations in the gene and to evaluate the functional effects of those mutations. In order to do
this, the genes of interest are sequenced from a panel of tumors and the sequence is
compared to the reference sequence. DNA from the patient’s constitutional DNA is then
analyzed to determine whether the variant in the tumor arose specifically within the tumor,
i.e., whether the change is somatic.
In the past, large scale mutational analysis of candidate genes was technically limited.
Several important advances have changed this. These include our ability to establish high
quality tumor banks, created either through generation of early passage tumor cell lines or
xenografts or through selective capture or microdissection of tumor cells. This allows the
detection of somatic mutations that are otherwise masked by neighboring normal tissue. In
addition, the completion of the human genome sequence coupled with vast improvement in
automated methods for large-scale sequence analysis of specific loci have allowed for rapid
and robust sequence analysis.18–21 The combination of these advances has now created an
opportunity for systematically identifying somatic mutations in human cancers and
evaluating the roles of such mutated genes in tumorigenesis.
MMPs are Somatically Mutated in Human Cancer
In the past, it was stated that the expression of MMPs in tumors was secondary to
transcriptional changes rather than genetic alterations.5 At that time, there were only two
reported genetic alterations in cancers, which were the translocation of the MMP23 genes in
neuroblastoma22 and amplification of the MMP24 gene.23 A large systemic analysis of
genetic alterations in human breast and colorectal cancers recently uncovered numerous
mutations in genes that were originally not associated with cancer. In this study,
approximately 22% of the candidate cancer (CAN) genes were involved in cell adhesion,
which includes the metalloproteinase family.18 This gave perspective and guidance in how
further cancers should be analyzed genetically.
Recently MMPs have been further investigated in melanoma and been shown to have a
significant genetic impact on MMPs correlation with cancer.24 As an initial screen to
evaluate whether MMPs are genetically altered in melanoma, the coding exons of all MMP
members were analyzed in a panel of 32 tumors. Sequences from these regions were PCR
amplified and directly sequenced from tumor DNA. Every identified genetic alteration was
checked in the matched normal DNA in order to determine whether it was somatic. Every
MMP gene that was found to have one somatic mutation or more was evaluated in an
additional 48 melanoma samples.
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From this analysis a total of 28 somatic mutations in eight MMP genes were identified,
involving 23% of the melanoma tumors analyzed. In order to determine whether the
alterations are passenger mutations, which are biologically neutral and do not affect the
growth of the cancer cell, or driver mutations which are involved in the development of the
cancer and have been positively selected over time, it is important to test if the ratio of
nonsynonymous:synonymous (NS:S) alterations is significantly higher than the NS:S ratio
predicted for non selected passenger mutations. The NS:S alterations detected in the
melanoma MMP screen was 28:5, which was significantly higher than the NS:S ratio of 2:1
predicted for nonselected passenger mutations, which led to the conclusion that these are
driver mutations. The mutations also had a significant ratio of C:G > T:A transitions, which
was noted as melanoma signature.25 MMP8 and MMP27 were the most frequently mutated
genes noted in these samples.24 Interestingly, both of these MMPs are on the same
chromosome 11 and they both have an identical protein domain structure. Ninety percent of
somatic mutations occur in one allele and dominantly develop the cancer. Ten percent of the
somatic mutations need both alleles to cause the protein to dysfunction and cause the
progression of cancer; these act in a recessive manner and are known as tumor suppressor
genes.25 MMP8 was further explored since it was one of the most frequently mutated MMP
genes (found in 6.3% of melanoma samples), most of its mutations were accompanied by a
loss of heterozygosity and because it has been previously shown to protect against skin
tumor development;8 all suggesting that MMP8 is a tumor suppressor gene.
Functional Effects of Wild Type MMP8 and MMP8 Mutations
MMP8 (collagenase-2) belongs to the group of extracellular proteases and has the ability to
degrade the extracellular matrix.26 Thus, it has been shown to have excellent capabilities of
degrading fibrillar collagens.27 However, MMP8 has many other substrates as well such as
other extracellular matrix proteins, proteases, cell adhesion proteins, protease inhibitors,
growth factors and chemokines.
Previous in vivo studies characterizing the effects of MMP8 on melanoma metastasis had
shown that overexpression of wild type MMP8 in melanoma cells reduces lung metastasis
formation. The mechanism for the reduced metastasis was found to be through increased
adhesion of cells expressing wild type MMP8 to type I collagen and laminin-1 when
compared with control cells. In addition, tumor cells overexpressing wild type MMP8 were
shown to have a substantially reduced invasive capability through Matrigel when compared
with control cells,11 again suggesting MMP8 to be a tumor suppressor gene.
The nature of the mutations identified in MMP8 described in the previous section also
suggested MMP8 to be a tumor suppressor gene. However, in order to confirm this,
functional evaluation of the mutations was necessary. To determine the biochemical
consequences of the mutations, wild type MMP8 or five of the mutations were
overexpressed HEK 293T cells and their matrix metalloproteinase activity was evaluated.
Expression of all the MMP8 mutants resulted in significantly less metalloproteinase activity
compared to wild type protein. The biological effects of the various MMP8 mutations were
then tested. When growth assays on plastic were performed, melanoma cells expressing wild
type or mutant MMP8 grew similarly. However, when growth on soft agar was evaluated,
wild type MMP8 substantially inhibited the number of colonies that formed. Similarly, when
MMP8 was knocked down in a melanoma cell line that expressed wild type MMP8, an
increase in anchorage independent growth was seen, thus phenocopying the overexpression
results. In vivo analysis of the MMP8 mutations involved subcutaneous injection of
melanoma cells overexpressing either wild type or mutant MMP8 into NOD/SCID mice.
Mice that were injected with wild type clones had no local tumor ulcerations or lung
metastases; however, mice injected with cells overexpressing the various MMP8 mutations
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developed tumor ulcerations and numerous tumor lung invasions.24 These compelling
findings conclude that MMP8 has a protective role, while mutations in MMP8 enhance the
progression of melanoma. A summary of the roles that wild type and mutant MMP8 have in
tumorigenesis is summarized in Figure 1.
Further Genetic Analyses
There has been undeniable evidence showing that the genetic mutations of MMP8 have a
significant effect on the functional activity of the protein and that it is a tumor suppressor. It
is indeed warranted based on this systematic genetic study that MMPs are genetically
evaluated in additional cancer types. In addition, to extend our knowledge of fundamental
roles of proteases in cancer progression, a complementary systematic sequence analysis of
all ADAMs and the related ADAMTS family would be a worthwhile endeavor. Similar to
MMPs, ADAM and ADAMTS belong to a superfamily of zinc-based proteinases, the
metzincins.28 Many members of the ADAM and ADAMTS families have been associated
with tumorigenesis and tumor progression. The exploration has already begun. Four somatic
mutations have been discovered in ADAMTS15 in 50 colorectal cancer samples.29
Functional analysis of these mutations has revealed that knockdown of this protease in
colorectal cancer cells promotes in vitro and in vivo tumor growth and invasion, and
overexpression of wild type ADAMTS15 reverses these phenotypes. In addition, in vivo
analysis has shown that ADAMTS15 knockdown markedly promotes in vivo tumor growth.
Thus, functional evaluation of this protease has revealed yet another tumor suppressor gene.
It is also remarkable that several ADAMTS genes including ADAMTS1, ADAMTS9,
ADAMTS12 and ADAMTS18 have been identified as epigenetically silenced genes in
several human carcinomas30–33 further validating the concept that different members of this
family of secreted metalloproteinases are inactivated in cancer and may function as anti-
tumor proteases.
Clinical Implications
Understanding the molecular changes that arise during cancer development is critical to the
development of rationally designed diagnostic and treatment strategies. This is currently the
practice with several different types of cancers such as the subclassification of acute myeloid
leukemia and the treatment of chronic myeloid leukemia34 and gastrointestinal stromal
tumors35 by using drug therapy to inhibit the mutated genes. As mentioned, in the past,
MMPs were associated with cancer metastasis5,36 and small molecule inhibitors of MMPs
were tested as potential anticancer agents. However, clinical trials using these inhibitors
showed no effect and, occasionally, accelerated tumor growth6,17,37 suggesting that an in-
depth analysis of the specific role of individual MMPs in particular cancer types is
necessary. The studies described above for MMP8 and ADAMTS15 together with previous
observations on the anti-tumorigenic properties of different proteases17 have identified anti-
targets for diagnostic and therapeutic intervention. Thus, the MMP inhibitors used in clinical
trials were possibly inhibiting the antitumor effects of certain MMPs. Recognizing that
particular extracellular proteases play a protective role in the development of cancer can
change the treatment of malignancies. Perhaps restoring the protective nature of certain
MMPs or increasing their proteolytic activity in tumors with a particular MMP mutation or
deficiency can hinder the progression of the cancer. This new era in which the sequence of
the human genome has been delineated, coupled with advances in high-throughput DNA
analyses have created an opportunity to more precisely characterize genetically the human
genome and in this case the degradome.38 Genetic, functional and structural evaluation of
the roles of mutated proteases in tumorigenesis will allow the discrimination between
proteases that promote cancer development and proteases that inhibit it. It is reasonable to
expect that such studies can lead to the design of novel inhibitors that are specific to
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particular proteolytic enzymes leading to individualized medicine and to improved disease
management.
Conclusions and Future Work
With the use of high throughput DNA sequencing, over the next couple of years, there can
potentially be a revolutionary change in the science of cancer. This has been already
accomplished for ADAMTS15 in colorectal cancer and the MMP family in melanoma, and
through sequencing and functional analysis, new tumor suppressors have been discovered.
This can be advanced and applied to the search for mutations of MMPs and other
extracellular proteases in various cancers. The detection of these mutations will initiate
further studies in the understanding of the role of these mutations and these particular genes
in cancers. Although MMP8 and ADAMT15 are now well established as tumor suppressors,
there is much speculation as of their roles in the progression of cancer. Further studies need
to be done on these proteins in order to understand the mechanism of their protective roles.
There still needs to be additional research done in this area to get a better understanding of
these proteases before it can be used in the clinical practice. Nonetheless, the research is
heading in the right direction and this will help to answer the questions of the complex
nature of cancer, possible roles of various genes in cancer, and new insight into the
treatment of malignancies.
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Figure 1.
Functional effects of wild type and mutant MMP8. Wild type MMP8 shows tumor
suppressive activities by maintaining its proteolytic activity and inhibiting various stages of
tumorigenesis, such as migration and metastasis. In contrast, mutant MMP8 loses its
proteolytic ability and enhances tumorigenic phenotypes.
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